Our top pick for
Tilly's, Inc is an apparel retail business based in the US. Tillys shares (TLYS) are listed on the NYSE and all prices are listed in US Dollars. Tillys employs 1,400 staff and has a trailing 12-month revenue of around USD$525.9 million.
|52-week range||USD$3.46 - USD$11.2|
|50-day moving average||USD$10.4433|
|200-day moving average||USD$8.1124|
|Wall St. target price||USD$12|
|Dividend yield||N/A (24.39%)|
|Earnings per share (TTM)||USD$0.018|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Tillys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tillys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tillys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 523x. In other words, Tillys shares trade at around 523x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Tillys's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9794. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Tillys's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Tillys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$12.7 million.
The EBITDA is a measure of a Tillys's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$525.9 million|
|Gross profit TTM||USD$240.2 million|
|Return on assets TTM||-0.89%|
|Return on equity TTM||-2.25%|
|Market capitalisation||USD$313.3 million|
TTM: trailing 12 months
There are currently 548,807 Tillys shares held short by investors – that's known as Tillys's "short interest". This figure is 4.9% down from 577,349 last month.
There are a few different ways that this level of interest in shorting Tillys shares can be evaluated.
Tillys's "short interest ratio" (SIR) is the quantity of Tillys shares currently shorted divided by the average quantity of Tillys shares traded daily (recently around 220404.41767068). Tillys's SIR currently stands at 2.49. In other words for every 100,000 Tillys shares traded daily on the market, roughly 2490 shares are currently held short.
However Tillys's short interest can also be evaluated against the total number of Tillys shares, or, against the total number of tradable Tillys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tillys's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Tillys shares in existence, roughly 20 shares are currently held short) or 0.0248% of the tradable shares (for every 100,000 tradable Tillys shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tillys.
Find out more about how you can short Tillys stock.
We're not expecting Tillys to pay a dividend over the next 12 months.
Over the last 12 months, Tillys's shares have ranged in value from as little as $3.46 up to $11.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Tillys's is 2.048. This would suggest that Tillys's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tilly's, Inc. retails casual apparel, footwear, and accessories for young men and women, and boys and girls in the United States. Its apparel merchandise includes tops, outerwear, bottoms, and dresses; and accessories merchandise comprises backpacks, hydration bottles, hats, sunglasses, ear buds, handbags, watches, jewelry, and others. The company also provides third-party merchandise assortment across its various product categories. As of February 1, 2020, it operated 240 stores in 33 states. The company also sells its products through its e-commerce Website, tillys.com. Tilly's, Inc. was founded in 1982 and is headquartered in Irvine, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.